{
    "nct_id": "NCT04285567",
    "official_title": "A Prospective, Open-Label, Multicenter Randomized Phase III Study to Compare The Efficacy and Safety of A Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/Bendamustine and Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL(17P) or TP53 Mutation",
    "inclusion_criteria": "* Ability to comply with the study protocol, in the investigator's judgment\n* Aged 18 years or older\n* Have previously untreated documented Chronic Lymphocytic Leukemia (CLL) according to the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria\n* CLL requiring treatment according to the iwCLL criteria\n* Cumulative Illness Rating Scale (CIRS) score ≤ 6 and creatinine clearance (CrCl) ≥ 70 mL/min\n* Hematology values within the following limits, unless cytopenia is caused by the underlying disease (i.e., no evidence of additional bone marrow (BM) dysfunction; e.g., myelodysplastic syndrome, hypoplastic BM):\n\n  * Absolute neutrophil count ≥ 1.0 x 109/L, unless there is BM involvement\n  * Platelet count ≥ 75 x 109/L and more than 7 days since last transfusion, or ≥ 30 x 109/L if there is BM involvement\n* Adequate liver function as indicated by a total bilirubin, aspartate aminotransferase, and Alanine transaminase ≤ 2 times the institutional upper limit of normal (ULN) value, unless directly attributable to the participant's CLL\n* Life expectancy >6 months\n* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception and agreement to refrain from donating eggs\n* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating sperm\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL)\n* Participants with Small Lymphocyclic Lymphoma (SLL) only\n* Known central nervous system involvement\n* Participants with a history of confirmed progressive multifocal leukoencephalopathy (PML)\n* Detected del(17p) or TP53 mutation (valid test within 6-months from screening is required for randomisation)\n* An individual organ/system impairment score of 4 as assessed by the Cumulative Illness Rating Scale (CIRS) definition limiting the ability to receive the treatment regimen of this trial with the exception of eyes, ears, nose, throat organ system\n* Participants with uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia\n* History of prior malignancy\n* Participants with infections requiring IV treatment (Grade 3 or 4) within the last 8 weeks prior to enrollment\n* Evidence of other clinically significant uncontrolled conditions including but not limited to active or uncontrolled systemic infection (e.g., viral, bacterial, or fungal)\n* History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products\n* Hypersensitivity to fludarabine, bendamustine, cyclophosphamide, rituximab, obinutuzumab, or venetoclax or to any of the excipients (e.g., trehalose)\n* Pregnant women and nursing mothers\n* Vaccination with a live vaccine ≤ 28 days prior to randomization\n* Prisoners or participants who are institutionalized by regulatory or court order or persons who are in dependence to the Sponsor or an investigator\n* History of illicit drug or alcohol abuse within 12 months prior to screening, in the investigator's judgment\n* Positive test results for chronic hepatitis B virus (HBV) infection (defined as positive hepatitis B surface antigen [HBsAg] serology)\n* Positive test result for hepatitis C (hepatitis C virus [HCV] antibody serology testing)\n* Participants with known infection with HIV or Human T-Cell Leukemia Virus 1 (HTLV-1)\n* Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study\n* Received any of the following agents within 28 days prior to the first dose of study treatment:\n\n  * Immunotherapy\n  * Radiotherapy\n  * Hormone therapy\n  * Any therapies intended for the treatment of lymphoma/leukemia whether approved or experimental\n* Participants who have received the following agents:\n\n  * Strong and moderate CYP3A inhibitors/inducers within 7 days prior to the initiation of study treatment\n  * Steroid therapy for anti-neoplastic intent with the exception of inhaled steroids for asthma, topical steroids, or replacement/stress corticosteroids within 7 days prior to the first dose of study drug administration\n  * Consumed grapefruit, grapefruit products, Seville oranges(including marmalade containing Seville oranges), or star fruit within 3 days prior to the first dose of study drug and throughout venetoclax administration\n* Inability to swallow a large number of tablets.",
    "miscellaneous_criteria": ""
}